Protagenic Therapeutics Inc. filings document a biopharmaceutical issuer with common stock and warrants, formal material-event reporting, governance changes, capital-structure disclosures and corporate-status records. The company’s SEC record includes 8-K reports on executive appointments and compensation arrangements, amended material-event filings, and disclosures tied to share-exchange transactions and related financial information.
Other filings cover Form 12b-25 notices for delayed quarterly reporting and Form 25 notifications involving removal of the company’s common stock and warrants from Nasdaq listing and Section 12(b) registration. These records also address material agreements, operating and financial results, clinical or regulatory disclosure categories, and public-company reporting obligations.